The key predictors for a future quality of drug development performance have been derived by us based on experience over decades. Although each project is performed once and is unique in many ways the probability of ending in a success depends on the structures and quality of interdisciplinary information exchange as well as on the capability of the expert persons involved.

We have developed tools including a rating tableau which allows ranking of evaluated projects and companies.

Our focus is about how the active participants handle interdisciplinary information exchange and how early they can detect unpredicted sources of later delays and how they are prepared to handle unforeseen 'adverse' facts.

This approach should help to make decisions prior to financial engagement or prior to the financiation round.